Dr. Campbell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
505 Parnassus Ave
San Francisco, CA 94143Phone+1 415-476-1525Fax+1 415-502-1976- Is this information wrong?
Education & Training
- University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2013 - 2015
- University of California (San Francisco)Residency, Internal Medicine, 2010 - 2012
- Indiana University School of MedicineClass of 2010
Certifications & Licensure
- CA State Medical License 2012 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Modulation of Hematopoietic Chemokine Effects in Vitro and in Vivo by DPP-4/CD26Timothy Campbell, MD> ;Libert. 2016 Mar 05
- 308 citationsNormal and Leukemic Stem Cell Niches: Insights and Therapeutic OpportunitiesKoen Schepers, Timothy B. Campbell, Emmanuelle Passegué> ;Cell Stem Cell. 2015 Mar 5
- Dipeptidylpeptidase 4 negatively regulates colony-stimulating factor activity and stress hematopoiesis.Broxmeyer HE Hoggatt J O'Leary HA Mantel C Chitteti BR Cooper S Messina-Graham S Hangoc G Farag S Rohrabaugh SL Ou X Speth J Pelus LM Srour EF Campbell TB> ;Nat Med. 2012 Dec
- Join now to see all
Journal Articles
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, M.D., Jesus Berdeja, M.D., Yi Lin, M.D., Ph.D., David Siegel, M.D., Ph.D., Sundar Jagannath, M.D., Deepu Madduri, M.D., Michaela Liedtke, M.D., Jacalyn Ro..., New England Journal of Medicine, 5/2/2019
Abstracts/Posters
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell TherapyTimothy B. Campbell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple MyelomaTimothy B. Campbell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Professional Memberships
- Member
- Member
- Member
Other Languages
- Spanish
Hospital Affiliations
- UCSF Medical CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: